Macquarie Group
CTKB icon

Macquarie Group’s Cytek Biosciences CTKB Stock Holding History

Macquarie Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,253,715
Closed -$10.7M – 1671
2023
Q2 		$10.7M Sell
1,253,715
-469,708
-27% -$4.21M 0.01% 771
2023
Q1 		$15.8M Buy
1,723,423
+670,687
+64% +$7.21M 0.02% 714
2022
Q4 		$10.7M Buy
+1,052,736
New +$14.1M 0.01% 819

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Macquarie Group's CTKB Position: Q3 2023 in Review

Macquarie Group sold out of Cytek Biosciences (CTKB) in Q3 2023, closing a stake of 1,253,715 shares — an estimated $10.7M sold.

Macquarie Group first reported a position in CTKB in Q4 2022 and held it in 3 quarters. The position peaked at $15.8M in Q1 2023. 106 funds tracked by Wall St. Rank hold CTKB as of Q3 2023.

  • Macquarie Group reported no remaining Cytek Biosciences position as of Q3 2023 after selling out during the quarter.
  • Macquarie Group sold 1,253,715 Cytek Biosciences shares in Q3 2023, an estimated $10.7M.
  • Macquarie Group first reported a position in Cytek Biosciences in Q4 2022 and held it in 3 quarters.
  • Macquarie Group's Cytek Biosciences position peaked at $15.8M in Q1 2023.
  • 106 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2023.

Based on Macquarie Group's 13F filing for Q3 2023, filed 14 Nov 2023.